However, aggressive forms may still occur, and personalized therapeutic strategies are increasingly required.<h4>Methods</h4>We performed integrated genomic and proteomic analysis of PTC tumor samples from patients who did not harbor BRAF or RAS mutations. This evidence concerns the gene BRAF and neoplasm.